Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021
Message from the CEO
As is well known, IBT is conducting a large phase III study (“The Connection Study”), the final study in our clinical development program with our drug candidate IBP-9414, which contains Lactobacillus reuteri as the active substance. The active substance is a naturally occurring bacterial strain found in women’s breast milk. The goal of our development is to offer physicians a unique treatment option which is partly intended to prevent very serious medical complications, such as NEC (necrotizing enterocolitis) and sepsis (blood poisoning), which occur when a child is born prematurely. In addition, our product is expected to improve the development of the stomach and intestines, which in turn leads to improved intestinal function and nutrient uptake.
In accordance with the study protocol, patient recruitment was paused on August 25 of infants in stratum A (the smallest infants with birthweights between 500-749g at birth) in anticipation of a safety review conducted by the Data Monitoring Committee (DMC). Recruitment was reinitiated September 22 following DMC’s completion of safety review. The DMC concluded that the signal which triggered the temporary recruitment pause did not represent a cause of concern and that there was no prospective medical reason to restrict recruitment of the smallest infants in the study. We reached a milestone of 600 recruited patients in September despite the temporary recruitment pause. During 2021 we also validated the second primary endpoint in “The Connection Study”. These two important events representing good momentum in our study and we are committed to continue to move forward with our study with accelerating speed.
The follow-on effects of COVID-19 for our study have started to subside although the virus represent a continued future uncertainty. We take note that the US recruitment pace in the US is significantly ahead of that in Europe and Israel. To date approximately 80% of recruited infants are born in the US. We have identified and mitigated several underlying causes for this trend which will hopefully increase the European pace such that it approaches the US momentum. The next planned DMC review is expected in Q4 2021, based on data from the first 600 randomized infants. This planned review will unlikely yield new conclusions given that the DMC recently completed its analysis on most of the same data in connection to the September recruitment pause.
We are as of today engaged with hospitals across 10 countries: the US, the UK, France, Spain, Poland, Hungary, Israel, Serbia, Romania and Bulgaria. There are currently 83 activated hospitals ready to include patients. An important KPI is track how many hospitals are actively recruiting patients. As of the end of March 2021, 51 hospitals had recruited at least one patient. Today that corresponding figure is 66 hospitals. We dedicate significant priority to further enhance this positive trend and expect to conclude the study during the end of 2022. IBT’s funding is expected to be sufficient for the completion of the study.
We received our Mexican patent approval on September 10. Patents were previously secured in China and Japan, strengthening our future IP protection of IBP-9414, which is of particular importance in countries where we do not have orphan drug status designation.
In conclusion, I would like to take this opportunity to express my appreciation to our employees and experts who with great commitment drive the work forward with our unique product which may play a major role for prematurely born children.
Stockholm, October 28st, 2021
Staffan Strömberg
CEO
Interim report January 1-September 30, 2021
|
Reporting period (Jan-Sep) 2021
|
* Operational income includes exchange rate effects on foreign currency deposits for the purpose of securing future outflows during the third quarter amounting to KSEK 7,313 (-3,872) and during the reporting period to KSEK 13,550 (3,384).
Significant events during the third quarter (Jul-Sep)
Significant events during previous periods in 2021
Significant events after the reporting period
No significant events have occurred after the reporting period.
Selected financial data | |||||
KSEK | 2021 Jul-Sep |
2020 Jul-Sep |
2021 Jan-Sep |
2020 Jan-Sep |
2020 Jan-Dec |
Net sales | – | – | – | – | – |
Other income | – | 79 | 94 | 233 | 312 |
Operating profit/loss | 228 | -18,586 | -28,485 | -45,294 | -71,918 |
Result after tax | -58 | -18,600 | -28,773 | -45,359 | -72,007 |
Total assets | 421,452 | 480,304 | 421,452 | 480,304 | 450,318 |
Cash flow for the period | -26,019 | -6,693 | -46,628 | -28,761 | -56,625 |
Cash flow per share for the period (SEK) | -2.32 | -0.60 | -4.15 | -2.56 | -5.04 |
Cash | 390,360 | 463,043 | 390,360 | 463,043 | 423,438 |
Earnings per share before and after dilution (SEK) | -0.01 | -1.66 | -2.56 | -4.04 | -6.41 |
Equity per share (SEK) | 36.65 | 41.43 | 36.65 | 41.43 | 39.21 |
Equity ratio (%) | 98% | 97% | 98% | 97% | 98% |
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (IBT) is a public company domiciled in Stockholm. The company’s Class B shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).
Infant Bacterial Therapeutics AB (publ) (IBT) is a pharmaceutical company with a product in clinical phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
For additional information please contact
Staffan Strömberg, CEO
Marie-Louise Alamaa, CFO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Telefon: +46 8 410 145 55
info@ibtherapeutics.com
www.ibtherapeutics.com
Publication
The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on October 29, 2021.
Attachments